WASHINGTON (Great Lakes News) – On Tuesday, Pfizer announced its experimental COVID-19 pill appears effective against the omicron variant.

In addition, the pharmaceutical giant said full results of its 2250-person study confirmed the drug reduced combined hospitalizations and deaths by roughly 89-percent among high-risk adults when taken shortly after initial onset of COVID-19 symptoms.

MORE NEWS: More Staff, More Spending, Same Results: Detroit Schools’ Academic Standstill

The Food and Drug Administration is expected to rule on whether to authorize Pfizer’s pill and a competing pill from Merck soon.